EP300 and chronic myelogenous leukemia, BCR-ABL1 positive: Thus we point out that a new route of c-Myc-mediated TXNIP suppression in CML cells, that BCR-ABL blocks TXNIP transactivation by disrupting a Miz-1–p300 complex via c-Myc induction, which was compromised in CML cells with imatinib treatment.